



Dear Colleague,

Welcome to the June edition of our Public Involvement update from the Public Involvement Programme (PIP) at NICE.

**NICE guideline on Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (Oct 2020)**

Please be advised that the draft scope consultation period for this NICE guideline will now run for an additional week (5 weeks in total). This means that the scope consultation period will start on 21 June 2018 and run until 5pm on 26 July 2018. We hope that your organisation will submit comments on the draft scope; it is a valuable opportunity to ensure that the guideline considers issues important to your members.

The lay member recruitment period will run in accordance with our scope consultation period, from 21 June 2018 to 26 July 2018. Please note that the recruitment period for the professional member committee positions will run for four weeks, from 21 June to 19 July.

You will be able to find all information on how to apply for any of our committee positions on our [Committee recruitment page](#) on our website from the 21 June 2018. Please circulate this link to any colleagues or networks you think may be interested.

If you have any further queries about this, please contact [CFSME@nice.org.uk](mailto:CFSME@nice.org.uk)

For more information about how we involve patients and the public in NICE's work please visit our [get involved](#) page on the NICE website. If you would like information on all of NICE's work, please subscribe to our [newsletters and alerts](#). NICE is also on Twitter – for news and updates please follow [@NICEComms](#). For messages specifically from the PIP follow us at [@NICEGetInvolved](#).

Register as a stakeholder organisation for the specific topics of interest to you. [NICE stakeholder registration](#).

If you have any comments about the content of this update or ideas about what you'd like to see in the next edition, please contact [sally.taylor@nice.org.uk](mailto:sally.taylor@nice.org.uk).

**Opportunities to get involved** (*click the header links*)

NICE committees and working groups are made up of health, social care and other professionals and practitioners, patients, service users, carers and members of the public and technical experts. Current vacancies are listed on [this page](#), all vacancies close at 5pm on the day of the deadline unless otherwise stated. This is a list of [vacancies](#) for patients, service users, carers and lay people.

**Current recruitment**

- **Tobacco prevention, cessation and harm reduction**  
Closes 5pm; 18 June 2018
- **Reveal LINQ insertable cardiac monitor to detect atrial fibrillation after cryptogenic stroke (a stroke with no known cause)**  
Closes 5pm: 11 July 2018

**Current consultations** (*Click the header links*)

We are aware that sometimes our [consultation deadlines](#) mean that it isn't possible for organisations to engage with their members as much as they might like. To try and help with this, NICE has a [database of milestone dates](#) for its clinical guideline programme. This means that you can see when consultations are scheduled in advance of the consultation starting. You can also see all the topics you might be interested in [registering as a stakeholder](#) for.

**Guideline**

- **Abdominal aortic aneurysm: diagnosis and management**  
Consultation end date: 29 June 2018
- **Atrial fibrillation: management**  
Consultation end date: 11 July 2018
- **Post-traumatic stress disorder (update)**  
Consultation end date: 23 July 2018

## Newly Published Guidance *(click the links)*

For the full list of last month's guidance, please click [here](#).

Ref	Title	Type
QS167	<b>Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups</b>	Quality Standard
QS168	<b>Cystic fibrosis</b>	Quality Standard
QS169	<b>Developmental follow-up of children and young people born preterm</b>	Quality Standard

## News (Click the header links)

- Hundreds of people with blood cancer given more treatment options after NICE recommends three drugs**  
NICE has recommended three blood cancer drugs, brentuximab vedotin, midostaurin and arsenic trioxide be made available on the NHS..
- NICE approves multiple sclerosis drugs after prices are reduced**  
Reductions to the price of three multiple sclerosis (MS) drugs mean NICE is now able to recommend them for routine NHS funding.
- Life-extending lung cancer drug will be more widely available on the NHS after NICE review**  
NICE says more people should be able to freely access pembrolizumab, known as Keytruda, after a new trial shows it helps certain adults with lung cancer live more than a year longer.
- Therapy offered within one month to prevent PTSD, says NICE**  
People who have suffered trauma and are at risk of post-traumatic stress disorder (PTSD) should be offered therapy within one month, NICE says in new draft guidance.

---

© NICE [2018]. All rights reserved. Subject to [Notice of rights](#).